Horizon Sees Blockbuster Future For Tepezza After US Approval
First Treatment For Thyroid Eye Condition
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat.